Julie Massicotte
Overview
Explore the profile of Julie Massicotte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boudriau S, Hanzel C, Massicotte J, Sayegh L, Wang J, Lefebvre M
Drugs R D
. 2016 Mar;
16(2):229-38.
PMID: 27028750
Background: Rapidly disintegrating or 'fast-melt' oral formulations have been developed recently to facilitate drug intake among patients. Even though these formulations have helped to improve therapy adherence, some of their...
2.
Filipe A, Almeida S, Pedroso P, Neves R, Marques S, Sicard E, et al.
Drugs R D
. 2015 May;
15(2):195-201.
PMID: 25939332
Aims: This bioequivalence study was conducted to assess the bioequivalence of two formulations, test and reference, of pregabalin 300 mg hard capsules, under fasting conditions. Methods: This was a single-center,...
3.
Boily M, Dussault C, Massicotte J, Guibord P, Lefebvre M
Eur J Pharm Sci
. 2014 Oct;
66:70-7.
PMID: 25312344
To demonstrate bioequivalence (BE) between two prolonged-release (PR) drug formulations, single dose studies under fasting and fed state as well as at least one steady-state study are currently required by...
4.
Paquette J, Rufiange M, Iovu Niculita M, Massicotte J, Lefebvre M, Colin P, et al.
Clin Ther
. 2014 Sep;
36(11):1650-64.
PMID: 25224876
Purpose: Trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) is a new drug intended to be used for the management of visceral pain in patients undergoing sedation-free, full colonoscopy. The objectives of this Phase I,...
5.
Tourigny J, Chartrand J, Massicotte J
Issues Compr Pediatr Nurs
. 2008 Jun;
31(2):89-101.
PMID: 18569199
Changes in health care delivery in Canada and Europe, especially the shift to ambulatory care, have modified the care that children and parents receive and have prompted the need for...
6.
Spenard J, Aumais C, Massicotte J, Brunet J, Tremblay C, Grace M, et al.
Br J Clin Pharmacol
. 2005 Sep;
60(4):374-7.
PMID: 16187969
Aims: To evaluate the effects of food and formulation on the pharmacokinetics of bismuth biskalcitrate, metronidazole and tetracycline when combined in a new 3-in-1 single capsule (BMT) for eradication of...
7.
Aumais G, Lefebvre M, Massicotte J, Tremblay C, Kasbo J, Brunet J, et al.
Drugs R D
. 2005 Apr;
6(1):41-6.
PMID: 15801866
No abstract available.
8.
Spenard J, Aumais C, Massicotte J, Tremblay C, Lefebvre M
J Clin Pharmacol
. 2004 May;
44(6):640-5.
PMID: 15145972
The objective of this study was to determine the impact of omeprazole on bismuth (Bi) bioavailability when given in a three-in-one capsule containing bismuth biskalcitrate, metronidazole, and tetracycline. Thirty-four healthy...
9.
Beaucage P, Massicotte J, Boileau J, Dumont L
J Cardiovasc Pharmacol
. 2003 Jun;
42(1):142-50.
PMID: 12827040
Calcium channel blockers (CCBs) have variable efficacy in the treatment of heart failure. We hypothesized that modulation of left ventricular diastolic pressure (LVDP) may play a role in the variable...
10.
Massicotte J, Viens A, Yao M, Leonardi A, Sironi G, Wang H, et al.
Acta Pharmacol Sin
. 2003 Mar;
24(3):199-206.
PMID: 12617766
Aim: Lercanidipine is a new vasoselective dihydropyridine calcium channel blocker with a short plasma half-life, long duration of action, and demonstrated cardioprotective properties. We hypothesized that it might be effective...